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NANOCONJUGATION; A CASE STUDY TOWARDS IMPROVING 
NANOPARTICLE-BASED THERAPEUTICS 
ALI KHANEHZAR 
Boston University Graduate School of Arts and Sciences, 2020 
Major Professor: Bjoern Reinhard, Professor of Chemistry 
ABSTRACT 
     Nanoparticles (NPs), nanometer scale materials possessing intriguing novel properties 
different from that of bulk materials of same nature, are proving to have a prodigious 
potential not only for improving current therapeutics but also for modulating fundamental 
processes of living organisms in the nanometer scale. Covalent attachment of a biological 
functionality to NPs, i.e. nanoconjugation, has, in fact, provided new opportunities for 
controlling and enhancing the function of molecular functionalities tethered to NPs.  
     Epidermal Growth Factor (EGF), a growth factor known to signal for cell growth after 
binding to EGF receptor (EGFR), has been indicated to enhance EGFR-mediated apoptosis 
in nanoconjugated form in EGFR-overexpressing cancer cells. Many aspects of the 
induction of apoptosis through nanoconjugated EGF remain, however, insufficiently 
understood. To address this knowledge gap, the work described in this thesis investigates 
the role of physicochemical NP properties, such as size, shape, core material composition, 
and EGF surface loading in enhancing EGF-mediated apoptosis in breast cancer cells. In 
particular, this thesis aims to elucidate the mechanism(s) through which nanoconjugation 
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changes the outcome of intracellular EGF-initiated cell signaling from cell growth and 
proliferation to apoptosis in EGFR-overexpressing breast cancer cells. 
      Data are presented that demonstrate that spherical NP-EGF with a diameter of 80 nm 
in core size show the highest efficacy in enhancing EGF-mediated apoptosis. These NPs 
were found to switch the outcome of EGFR signaling from growth and proliferation to 
apoptosis by modulating EGFR-mediated generation and activity of intracellular signaling 
molecules, such as reactive oxygen species (ROS) and Mitogen-activated protein kinases 
(MAPKs) family enzymes, in particular, c-Jun N-terminal kinases (JNKs). Intriguingly, it 
was found that nanoconjugated EGF was particularly effective in inducing apoptosis in 
difficult-to-treat EGFR-overexpressing basal-like breast cancer cells known for poor 
prognosis. Furthermore, some experimental observations indicate that nitric oxide 
inhibitors and NP-EGF show potential to synergistically enhance EGF-mediated apoptosis. 
This finding suggests a potential cell protective role for the EGFR-induced nitric oxide 
generation and introduces a potential therapeutic approach to improve cancer therapeutics.  
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1 Chapter 1 
Introduction, and significance 
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1.1 Nanoparticle (NP) definition, history 
NPs or ultrafine particles are usually referred to particles with a size in the range of 
1 to 100 nano-meters (nm). Interest in NPs arises from the novel properties of materials at 
nanoscale which differentiate them from bulk materials [1]. However, NPs are not 
necessarily materials in the range of 1 to 100 nm, but novel properties at nanoscale which 
is not observed in bulk materials is what defines them rather than their size. Surprisingly, 
NPs are not the result of modern research, and the history of metallic NPs with interesting 
optical properties goes back to many centuries ago with decorating applications in 
glassware; an example is use of gold NPs in the famous Lycurgus Cup manufactured by 
Romans in the 4th century [2] (figure 1). The emergence of nanotechnology goes back to 
150 years ago when Michael Faraday presented his research on ‘Experimental Relations of 
metals to Light’ to the Royal Society of London.1 The origin of modern nanotechnology is 
believed to be from Richard Feynman, “the 1965 noble prize laureate in physics”. “There 
is plenty of room at the bottom” is the title of a lecture he presented at American Physical 
Society in 1959, when he proposed the idea of manipulating materials at atomic scale. The 
idea of synthesizing and manipulating nano-scale materials was further developed and 
found a huge interest in the 21st century expressing the potential of nanomaterials to study 
and solve fundamental processes of living creatures with applications in the area of “nano-
medicine”. Some main applications of nanomaterials in nanomedicine will be introduced 
here. 
 
1 M. Faraday Philos. Trans. R Soc. Lond., 147 (1857), p. 145 
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Fig.  1-1 Use of gold NPs in Lycurgus Cup manufactured by Romans in the 4th century [2].2 
1.2 NPs application in biology and medicine 
One outstanding property of NPs is their comparable size with biomolecules and 
biological entities (virus, cells, and biomolecules) making them a great candidate for 
biological applications such as Bioanalytical assays, that use NPs as labels to detect and 
study cells, proteins, nucleic acids, and lipids [3]–[6], or separation and purification of 
biomolecules by utilizing magnetic NPs.  
Perhaps the most significant application of nanotechnology is nanomedicine, “a branch of 
medicine that applies the knowledge and tools of nanotechnology to the prevention and 
treatment of diseases. Nanomedicine involves the use of nanoscale materials, such as 
biocompatible NPs and nanorobots, for diagnosis, delivery, sensing or actuation purposes 
in a living organism.”3 NP-based drug delivery is a subcategory of nanomedicine which 
 
2 Reprinted from publication title “The fascinating world of nanoparticle research,” vol. 16, no. 7–8, pp. 
262–271, 2013. F. J. Heiligtag and M. Niederberger, Mater. Today, copyright (2013) with permission from 
Elsevier 
3 https://www.nature.com/subjects/nanomedicine 
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has been studied with an increasing rate recently due to capability of NPs to reduce drug 
toxicity by targeting specific cells/organs and increasing drug bioavailability.  
Utilizing NPs for drug delivery is of great interest for the following main reasons: 
NPs can be engineered in a way to mimic biological entities to reduce toxicity and 
immunogenic responses. NPs are capable of reducing toxicity of drugs through passive or 
active targeting to the desired body tissues [12], [13]. NPs can protect molecules such as 
nucleic acids from biodegradation by encapsulation, and enhance their delivery and 
availability to desired cells and related organelles [14]–[16]. Due to novel properties of 
nanoscale materials, NPs can enhance drug efficacy by modulating cellular processes such 
as endocytic pathways [17]–[21] and downstream signaling [22]–[24]. 
Despite huge potential for addressing longstanding health-related challenges, NPs can 
themselves cause or enhance toxicity due to nano-scale specific properties. The difference 
between bulk and nanomaterials necessitates more fundamental studies into their 
interactions with biological entities. The obtained gain in knowledge could be utilized to 
tune their properties to specific applications such as terminating cancer cells or delivering 
therapeutics selectively to diseased cells.  
 
1.3 NPs to explore fundamental properties of living organisms 
NPs with comparable size with biomolecules are potential tools to explore and study 
fundamental properties of living cells/organisms. For instance, the large optical cross-
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section of noble metal NPs with localized plasmons and their ability to couple has been 
utilized to study cell surface membrane receptors organization [7], [8]. Importantly, NPs 
can be engineered to mimic pathological entities, such as viruses. These NPs are precision 
model systems to study their pathological behavior under defined conditions. This 
approach can lead to new therapeutic strategies to fight viral diseases [9]–[11]. We can, 
however, not only obtain a greatly improved understanding of how mother nature behaves, 
but also finding new therapeutic strategies for a variety of diseases. 
 
1.4 NPs application in treatment of cancer 
1.4.1 What is cancer? 
Cancer is a disease which is related to abnormal uncontrollable growth and 
proliferation of the cells in the body capable of destroying body tissues. Cancer originates 
from genetic abnormalities inherited from parents or caused by damage to DNA during 
lifetime.4 If not prevented, and not diagnosed early, cancer can lead to serious health issues 
and ultimately death which further shows the significance of attention to this specific 
disease. 
1.4.2 What is Breast cancer and why does it need attention? 
Breast cancer is a type of cancer that originates from breast cells. “Breast cancer is 
the second most common cancer in women and men worldwide. In 2012, it represented 
 
4 https://www.cancer.gov/about-cancer/understanding/what-is-cancer 
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about 12 percent of all new cancer cases and 25 percent of all cancers in women.” “Since 
2008, worldwide breast cancer incidence has increased by more than 20 percent. Mortality 
has increased by 14 percent.”5 
These statistics fully clarifies the significance of further studies for developing therapeutics 
for (breast) cancer treatment. 
1.4.3 Classification of breast cancer cells? 
Breast cancer cells can be classified into 4 main categories: 
1) Luminal A 
2) Luminal B 
3) Triple negative/basal like 
4) HER2 enriched 
Among these cell lines, Luminal types grow more slowly and are known for 
relatively better prognosis, in contrary to basal like breast cancer cell lines (BLBCs) with 
higher growing rate and poor prognosis. Although there has been a significant advance in 
cancer therapeutics in recent years, treatment remains challenging especially for 
aggressive, metastatic cancer cells with poor prognosis. The main challenge here, is 
difficult-to-treat BLBCs due to their lack of estrogen receptor, progesterone receptor and 
HER2 that makes them more difficult to treat and target [25]. Here, new therapeutic 
 
5 https://www.bcrf.org/breast-cancer-statistics 
7 
 
strategies that can overcome these biologic barriers to terminate/normalize cancer cells 
will be of great significance. 
1.4.4 NPs as delivery systems for cancer treatment 
NPs are capable of contributing significantly not only by reducing drug side effects 
and non-specific toxicity to normal cells but also due to their capability of accumulating in 
tumors through a natural process called EPR (the enhanced permeability and retention) 
(figure 1-2) i.e. the concept of passive targeting [26]–[28]. In addition, NPs surface 
properties can easily be engineered with desired ligands facilitating more specific and 
efficient targeting to tumor sites, i.e. the concept of active targeting [29]–[32].  
Fig.  1-2 EPR effect [33].6 
 
 
6 Reprinted from publication title Radiolabeling of Nanoparticles and Polymers for PET Imaging. Stockhofe 
K, Postema JM, Schieferstein H, Ross TL. Pharmaceuticals (Basel, Switzerland). 2014 ;7(4):392-418. DOI: 
10.3390/ph7040392. Copyright (2014). 
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1.5 Epidermal Growth Factor Receptor (EGFR) as a target to treat cancer cells 
1.5.1 What is EGFR? 7 
EGFR, 134 KDa in MW, is a cell 
surface membrane receptor which signals for 
cell growth, proliferation, and apoptosis 
inhibition upon binding to EGF, a growth 
factor and peptide about 6.2 KDa in molecular 
weight. Upon binding to EGF, EGFR 
undergoes a conformational change, 
dimerizes and crossphosphorylates tyrosine 
kinases located in the cytoplasmic domain of 
the receptor initiating a cascade of 
phosphorylation reactions and downstream 
signaling that leads to gene transcription in 
the nucleus (figure 3) [34], [35]. 
1.5.2 EGFR signaling in cancer 
EGFR is overexpressed in many cancer cell lines [36]–[40] which makes it a 
potential target molecule to deliver therapeutics to cancer cells. It has been shown that 
EGFR can signal for apoptosis in EGFR overexpressing cell lines if exposed to high doses 
of EGF [41]–[45], indicating EGFR overexpression as a property of most cancer cells that 
 
7 Figure 3: https://en.wikipedia.org/wiki/Epidermal_growth_factor_receptor. Copyright. 
Fig.  1-3 EGFR signaling (Wikipedia.com) 
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can be utilized and even further enhanced against them. In fact, activated EGFR in the 
limiting membranes of the endosomes has been shown to signal for apoptosis [45]. 
Whether EGFR signals for apoptosis or cell survival depends on the receptor location 
(spatial regulation of EGFR signaling) [46]–[48], rate of endocytosis and receptor 
trafficking (temporal regulation of EGFR signaling) [49], [50], and receptor clustering 
[51], [52]. 
Thus, by modulating EGFR signaling spatiotemporally or by modulating EGFR cell 
surface distribution and clustering, we might be able to switch the signal from growth to 
apoptosis. 
1.5.3 Nanoconjugattion can modulate EGFR signaling 
Conjugation of EGF to NPs has been shown to modulate EGFR signaling. L. Wu 
et al showed that nanoconjugated EGF8 enhances EGF-induced apoptosis in EGFR 
overexpressing A431 cells [53]. They further studied the effect of nanoconjugated EGF in 
prolonging EGFR endosomal signaling by slowing down its endosomal trafficking 
pathway [54]. The fact that nanoconjugated ligands can exhibit a completely different and 
even opposite effect compared to their surface-loaded ligands in the free form, indicates 
the need for more fundamental studies about how NPs and their physicochemical properties 
such as size, shape, surface charge, and surface ligand density can modulate cellular 
processes. 
 
8 Conjugation of EGF with nanoparticles 
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1.6 Effect of NPs physicochemical properties on NP-cell interactions 
When designing NP-based therapeutics, the first thing that must be taken into 
consideration is how NPs interact with the biological entities and target cells, which 
depends on NP physicochemical properties. The first important properties of a biomaterial 
are biocompatibility and/or biodegradability. In case of NPs, other properties such as size, 
shape, surface charge, type of surface ligand and its density are also of great significance, 
due to nano-scale properties of materials, in order to enhance efficacy and reduce toxicity. 
If delivery is the aim, NP surface must be engineered in a way to reduce NP induced 
immune response and undesired protein corona formation, and to increase circulation time. 
NP physical properties such as size and shape must be designed to have optimum cargo 
loading, release, and cellular uptake simultaneously. Bellow, most important 
physicochemical properties of NPs are introduced. 
1.6.1 NP size 
Size of NPs plays a crucial role in modulating cellular processes. A lot of studies 
has been done to study the effect of NP size on cellular processes such as endocytic 
mechanisms [55]–[57], uptake efficiency [58], signaling pathways, apoptosis [59]–[61] 
etc. Several studies have shown that 50 nm spherical NPs show the highest uptake rate 
[55], [62]–[64]. Different NP sizes are also endocytosed via different endocytic pathways. 
Size of NPs endocytosed by clathrin-mediated pits has been reported to be  <200 nm 
whereas NPs above 200 nm start to be internalized via caveolae mediated endocytosis 
11 
 
which becomes predominant for NPs with about 500 nm in size [65], [66]. Fig 4 shows a 
schematic of different endocytic pathways of NPs known so far. 
 
Fig.  1-4 Schematic of endocytic pathways [28].9 
 
1.6.2 NP surface ligand density 
NP surface ligand density also plays an important role in cellular uptake efficiency. 
D.R. Elias et al, showed that 50 nm NPs show significantly different uptake rate based on 
their surface ligand density. In fact, similar to size, there is an optimum ligand density 
which leads to the highest uptake efficiency [51], [67].  Therefore, when describing a NPs 
behavior in terms of cellular uptake efficiency, surface ligand density should be also 
considered since it may shift the optimum NP size for higher uptake efficiency. 
 
9 Reprinted from publication title “Strategies for the intracellular delivery of nanoparticles,” vol. 40, no. 1, 
pp. 233–245, 2011, L. Y. T. Chou, K. Ming, and W. C. W. Chan, Chem. Soc. Rev., copyright (2011). 
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Significance of surface ligand density further emerges when the aim is studying or utilizing 
active targeting of NPs indicating the importance of optimizing NPs based on not only size 
but also ligand surface density to obtain the most efficient and desired modulation of 
cellular processes such as cell uptake for delivery applications or modulation of cell 
signaling pathways for therapeutic applications.  
1.6.3 NP shape 
NPs can be synthesized in a variety of shapes such as spheres, rods, stars, tubes, 
triangles, etc. Cells also behave differently when they interact with NPs with different 
shapes. Long nanorods and NPs with sharp edges has been shown to have higher binding 
and cellular uptake rate [21], [68]. However, they can induce a higher cytotoxicity 
compared to nanospheres, which is also cell type dependent [69].   
An important point to consider when studying the effect of NP physicochemical 
properties on cell-NP interaction is the fact of contribution of several NP physicochemical 
factors in the overall cellular response to NPs. Cell type, cell media, type of experiment (in 
vitro/in vivo), NP concentration, size, shape, NP surface ligand type and density, all 
influence the way cells interact with NPs. This may cause different studies appear to have 
contradictory results. In conclusion, it is difficult to generalize a single NP property with a 
specific cell response and still more detailed and in-depth studies on NP-cell interactions 
are required and NP design must be optimized based on the desired, specific application.  
13 
 
1.7 NPs and cell signaling pathways 
1.7.1 What is cell signaling 
“Cell signaling refers to the vast networks of communication that occur between 
and within each cell in our body. Unlike the stable bricks that lay the foundation of our 
houses, cells are dynamic and ever-active building blocks. In effect, cell signaling makes 
this possible.”10 Here, the intracellular communication system aspect of cell signaling is 
our focus. The three stages of cell signaling are: 
1. Reception, the stage when signal molecule binds a cell surface receptor 
2. Signal transduction, the stage when the signal initiates a series of enzymatic 
reactions called signal transduction cascade. 
3. Response, which is the cellular response such as cell growth, proliferation, 
differentiation, migration, or apoptosis. 
Due to their nanometer-scale properties, NPs can initiate cell signaling pathways 
or, in case of nano-conjugation, even a different cell signaling pathway compared to their 
surface ligand or loaded cargo. The significance of studying NP-induced/enhanced cell 
signaling pathways arises, when therapeutic application of NPs is the aim in order to design 
highly efficient and effective NPs with minimal undesired side effects and capability of 
initiating or enhancing desired cell signaling pathways.  
 
10 https://biologydictionary.net/cell-signaling/ 
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1.7.2 NP-induced/enhanced generation of reactive oxygen species (ROS), nitric oxide 
(NO) 
1.7.2.1 What are ROS and NO? 
Reactive oxygen species are chemically reactive species which contain oxygen. 
ROS are produced by NADPH oxidases enzymatic activity whereas NO is produced by 
enzymatic activity of nitric oxide synthases (NOS). Peroxides, superoxides, hydroxyl 
radicals, singlet oxygen, and alpha-oxygen are ROS. 
1.7.2.2 ROS and NO as second messengers in cancer 
ROS and NO have been proved to act as second messengers [70]–[73], i.e. 
intracellular signaling molecules that can trigger cell survival or apoptosis signals in 
response to extracellular signaling molecules. ROS/NO have been shown to signal for cell 
survival or apoptosis dependent of their intracellular levels. When low ROS levels has been 
shown to effectively regulate mitosis, cell growth, proliferation and angiogenesis in cancer, 
high ROS levels are linked with toxicity in cancer cells [74], [75]. Figure 5 shows how 
ROS regulates cellular processes. As shown in the figure, moderate ROS levels promote 
tumorigenesis whereas high levels are toxic to cancer cells.  
15 
 
 
Fig.  1-5 ROS signaling is dose-dependent [75].11 
 
Similar to ROS, NO has also a dual role in cancer which is concentration dependent [76]–
[78] (figure 1-6).  
 
11 Reprinted from publication title “ROS Function in Redox Signaling and Oxidative Stress Michael,” vol. 24, 
no. 10, pp. 1–25, 2015. A. Manuscript and O. Stress, Curr Biol. copyright (2015). 
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Fig.  1-6. Role of NO in cancer is concentration-dependent [79].12 
 
1.7.2.3 Mechanism of ROS and NO signal initiation 
Mechanism of ROS redox signaling involves oxidation of cysteine residues within 
proteins. “Cysteine residues exist as a thiolate anion (Cys-S-) at physiological pH and are 
more susceptible to oxidation compared to the protonated cysteine thiol (Cys-SH). During 
redox signaling, H2O2 oxidizes the thiolate anion to sulfenic form (Cys-SOH) causing 
allosteric changes within the protein that alters its function.” [75]. ROS has been shown to 
activate MAPK and ERK signaling pathways [80]. Figure 7 shows major ROS signaling 
pathways. 
NO signaling activity derives from its redox reactivity and nitrosylation of thiols in 
enzymes such as kinases, caspases, etc [81]–[84]. NO has also been linked to activating 
oncogenic pathways, and EGFR signaling and stimulating tumorigenesis [82].   
 
12 Reprinted from publication title “The Potential Role of Nitric Oxide in Halting Cancer Progression 
Through Chemoprevention,” vol. 21, no. 1, pp. 1–12, H. Vahora, M. A. Khan, U. Alalami, and A. Hussain, J. 
Cancer Prev. copyright (2016) 
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Fig.  1-7. ROS signaling pathways in cancer [85].13 
 
1.7.2.4 EGFR-mediated generation of ROS/NO 
EGFR signaling is important in understanding tumor progression due to its vital role 
in signaling for cell survival and tumor progression. Therefore, understanding the interplay 
between EGFR and ROS signaling is required for understanding mechanism of tumor 
progression [86]. It has been shown that EGFR activation can result in localized generation 
of H2O2 through NADPH oxidases. Generated ROS can modify specific cysteine residues 
in the EGFR active site leading to activation of intracellular signaling cascades [86]. EGF 
has also been shown to activate NOS and NO generation through EGFR signaling [77], 
[87]. The role of NPs in enhancing EGF-induced ROS has not been studied before. 
 
13 Reprinted from publication title “Reactive oxygen species signaling in cancer: comparison with aging.,” 
vol. 2, no. 3, pp. 219–30, 2011. I. Afanas’ev, Aging Dis., copyright (2011). 
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Considering the role of ROS as an important signaling molecule it is important to 
understand how NPs modulate ROS generation and signaling. 
 
1.8 NPs and enhancing drug potency  
It has been shown that combination of drugs and NPs can synergistically enhance the 
efficacy of drugs. Y. G. Yuan et al showed that silver NPs can enhance apoptotic efficacy 
of gemcitabine in human ovarian cancer cells [88]. It can be an evidence that in addition to 
the capability of NPs to deliver cargo more efficiently to the target cells, NPs may exhibit 
new properties in enhancing cargo efficacy which is not necessarily due to delivering more 
cargo. This Potential role of NPs as not only drug carriers but also enhancing drug 
efficacy is intriguing and proposes not only new NP-based approaches for therapeutics 
but also may reveal novel properties of NPs in this context, that needs to be further studied. 
 
1.9 Aim and significance 
Despite the existence of many studies in the area of NP-cell interactions, there is still a 
need for more detailed and specific study of how NPs with different physicochemical 
properties interact with cells, and the mechanism of interaction to find optimum NP 
properties for improving therapeutic and drug delivery applications. Here, we worked on 
effect of NP physicochemical properties on NP-cell interactions in order to design a NP 
platform for enhancing delivery and efficacy in inducing death in cancer cells. To gain a 
19 
 
better understanding of NP-cell interaction, we also studied apoptotic signaling pathways 
mediated by our designed NPs. Our study can be classified into the following categories: 
 Nanoparticle-cell interactions induced apoptosis: a case study with nanoconjugated 
epidermal growth factor 
Epidermal Growth Factor Presenting Polymer Nanoparticles Stimulate Nitric 
Oxide Generation and Modulate Apoptotic Signaling through Nitrosylation of JNK 
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2 Chapter 2 
Nanoparticle–cell interactions induced apoptosis: a case study with nanoconjugated 
epidermal growth factor 
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1.1 Introduction 
The epidermal growth factor (EGF) receptor (EGFR) is a transmembrane receptor and a model 
receptor tyrosine kinase (RTK). EGFR is rapidly endocytosed after activation through ligand 
binding and subsequent dimerization.1 EGFR signaling is key for healthy cell growth and 
differentiation, but EGFR overexpression or dysregulation is associated with uncontrolled cell 
growth and cancer.2,3 The medical relevance of EGFR is, however, not limited to cancer. This 
receptor is also important for regulating neural plasticity4,5 and intestinal barrier function,6 and 
represents a therapeutic target in Alzheimer's disease.7 Intriguingly, EGFR signaling can, under 
specific conditions, also block proliferation and initiate a programmed cell death (apoptosis) 
pathway.8–10There is now mounting evidence that this apparent contradiction results from a 
perturbation of the spatial regulation of EGFR signaling. Although EGFR is activated through 
ligand binding at the cell surface, activated EGFR signaling continues after uptake until the 
EGFR containing endosome having the phosphorylated EGFR tail exposed in the cytoplasm is 
enclosed in a multivesicular body, or the EGF-EGFR complex is degraded. In the case of free 
EGF it was hypothesized that the signaling outcome can vary with the cellular location of 
signaling.11 Indeed, accumulation of activated EGFR in the limiting membrane of early 
endosomes was shown to trigger apoptosis.12–15 
EGF-EGFR recognition is utilized to target cancer cells for diagnostic and therapeutic 
purposes with NP.16–19 The rational development of optimized targeting strategies requires a 
detailed understanding of NP–cell interactions during and after uptake.20–24 A particularly 
important question for a ligand–receptor pair, such as EGF-EGFR, whose signaling is 
potentially spatially regulated, is whether nanoconjugation of the ligand and its consequences 
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on uptake and intracellular trafficking impact the signaling outcome and whether this effect by 
itself has therapeutic potential. Indeed, recent studies have found that conjugation of EGF to 
gold NP results in apoptosis, as evidenced by increased caspase-3 levels, nucleus condensation, 
and Annexin V/propidium ion staining patterns, at a much lower concentration than observed 
for the free ligand.25 The gain in apoptotic efficacy due to the nanoconjugation of EGF was 
confirmed in both EGFR overexpressors (A431, MDA-MB-468) as well as in cells with 
physiological EGFR expression levels (HeLa).25,26 The mechanism by which nanoconjugation 
of EGF “switches” the signaling outcome from proliferation to apoptosis and how the effect 
depends on the physico-chemical properties of the NP core remain, however, unclear. As an 
important first step towards an improved understanding of the underlying NP–cell interactions 
that modulate EGF signaling, we characterize in this work the dependence of NP-EGF induced 
apoptosis on the intrinsic NP parameters size, shape, and EGF surface loading and elucidate the 
role of NP-EGF induced oxidative stress in inducing apoptosis. 
2.1 Experimental 
2.1.1 NP functionalization with EGF 
100 μL of 10 mM PEG1 (HS–(CH2)11–(C2H4O)6–COOH) and 10 μL of 10 mM PEG2 (HS–
CH2CH2–(C2H4O)77–N3) solutions were added to 20 mL of gold nanosphere colloids and 
incubated overnight at room temperature. The particles were then washed twice by 
centrifugation and resuspension in millipore water. Subsequently, 2 μL of a 100 mg 
mL−1 propargyl-N-hydroxysuccinimidyl ester (C10H11NO5) solution in DMSO were added to 
100 μL of a 1 mg mL−1 solution of EGF in 1× PBS, pH 7.4, and incubated on ice for 6 h. This 
mixture was then dialyzed against 0.5× PBS for 72 h. 5 μL of the obtained propargyl-PEG-EGF 
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(concentration 10 nM) were then incubated overnight at 4 °C with 1 mL of the PEGylated gold 
nanospheres in the presence of 500 μM ascorbic acid and 100 μM CuSO4 (catalyst for the 
cycloaddition reaction). The resulting EGF-functionalized particles (NP-EGF) were washed by 
centrifugation (2×) and resuspended in 1 mL of DMEM. 
2.1.2 NR pegylation and functionalization with EGF 
2.5 μL of 10 mM solutions of PEG1 and PEG2 were added to 1 mL of Au NR colloid 
(concentration = 100 pM) in the presence of 3% v/v of Tween 20 and subsequently incubated 
under soft stirring overnight at room temperature. The PEGylated Au NRs were washed twice 
by centrifugation (7500–15 000 rpm, 15 min–40 min depending on the NP dimensions) and 
resuspended in millipore water. 2 μL of a 100 mg mL−1 propargyl-PEG-NHS ester solution in 
DMSO were added to 100 μL of a 1 mg mL−1solution of EGF in 1× PBS, pH 7.4, and incubated 
in an ice bath for 6 h. This mixture was then dialyzed against 0.5× PBS for 72 h with a 3.5 kDa 
molecular weight membrane. 10 μL of the obtained propargyl-PEG-EGF were incubated 
overnight at 4 °C with 1 mL of PEGylated Au NR colloid containing 500 μM ascorbic acid and 
100 μM CuSO4 as the catalyzer for the cycloaddition reaction. The resulting EGF-
functionalized rods (NR-EGF) were washed 2× by centrifugation (7500–15 000 rpm, 15 min–
40 min depending on the NR size). After that, NR-EGF was resuspended in 1 mL DMEM. 
2.1.3 Caspase-3 activity and quantification of apoptosis enhancement 
MDA-MB-468 cells were plated in 6-well dishes. After ≈80% cell confluency was reached the 
growth medium was replaced by fresh medium containing NP or free EGF ligand controls. The 
cells were incubated with the NP preparations for 4 h and then washed three times with Hank's 
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buffer. After that the cells were further incubated in growth media for 20 h. Finally, the particles 
were trypsinized with 0.5 mL of a 0.25% trypsin–EDTA solution. The trypsinization was 
quenched after 5 min by adding 0.5 mL of complete medium in each well. The cells were 
collected by centrifugation (300g, 5 min) and washed once with 1× PBS. Subsequently, the cells 
were resuspended in 1× PBS (800 μL). The EnzChek® Caspase-3 assay was applied to 
determine apoptosis activity according to the manufacturer's protocol in a 96-well plate. 
Fluorescence was quantified with a PerkinElmer 1420 Victor-3 multi-label counter using 
excitation and emission wavelengths of λexc = 485 nm and λem = 535 nm, respectively. The 
apoptosis enhancement was calculated from the measured caspase-3 levels as the change in 
apoptosis relative to the no treatment control. All caspase-3 activities were normalized by the 
total protein concentration determined by a BCA assay to account for the differences in sample 
size. 
2.1.4 ROS quantification 
Flow cytometry was used to quantify ROS generation. Cytoplasmic ROS generation was 
quantified using the CellROX deep red flow cytometry assay kit (Invitrogen, C10422). 1 mM N-
acetylcysteine (NAC) was used as an antioxidant to suppress ROS generation and 200 μM tert-
butyl hydroperoxide (TBHP) was used as a positive control to induce ROS. Mitochondrial 
superoxide levels were quantified with a MitoSOX Red Mitochondrial Superoxide Indicator 
(Invitrogen, M36008). This compound is a hydroethidine derivative that selectively localizes to 
the mitochondria. 
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2.1.5 GSH quantification 
Cellular GSH levels were measured with the GSH/GSSG ratio detection assay kit (Fluorimetric-
Green) following the manufacturer's protocol (Abcam, ab138881). GSH levels were evaluated 
after incubation for 4 h with NP78.9-EGF. 
2.1.6 Mitochondrial membrane potential assay 
The cells were cultured in 6-well dishes. 20 μM tetraethylbenzimidazolylcarbocyanine (JC1) 
was added to the control and sample wells and incubated for 10 min at 37 °C. The wells were 
washed with Hank's buffer (HBSS) twice before NP78.9-EGF was added and incubated for 4 h. 
4 μl of carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) was included as a 
positive control. The cells were detached, washed with PBS and then analyzed through flow 
cytometry with an emission wavelength of 590 nm. 
2.1.7 ICP-MS quantification of cellular NP uptake 
MDA-MB-468 cells were plated in 6-well dishes. After 24 h, the old growth medium was 
replaced with a fresh medium containing nanoconjugated EGF, with the NP-EGF concentration 
varying depending on the NP core size between 8–128 pM, or PEGylated NP at a concentration 
of 100 pM for 4 h and then washed three times with Hank's buffer. After that the cells were 
further incubated in growth media for 20 h before they were trypsinized with 1 mL of 0.25% 
trypsin-EDTA solution and subsequent quenching of the enzyme by the addition of 1 mL of 
complete medium in each well. The cells were collected by centrifugation (200g, 5 min) and 
subsequently washed twice with 1× PBS. The cell densities of the samples were determined 
through a hemacytometer (no less than 200 cells). Aqua regia (1 mL) was added to the cells in 
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a total volume of 10 μL to dissolve the Au NP. The mixture was then dried overnight at 65 °C 
and re-dissolved in HCl solution (1 mL, 2%). After an additional 4-fold dilution through 
millipore water, the samples were inserted into a VG Plasma Quad ExCell ICP-MS. For etching 
control experiments an additional step was performed before trypsinization. 1 mL of the I2/KI 
aqueous solution (0.34 mM I2, 2.04 mM KI in PBS) was added to the culture well and incubated 
at room temperature for 2 min and then washed 3 times with pre-warmed Hank's buffer. 
2.1.8 Quantification of EGFR phosphorylation 
NP-EGF was incubated with MDA-MB-468 cells in DMEM for defined time durations. The 
cells were washed in Hank's buffer to remove the particles and then detached and lysed. The 
lysate was diluted 10× before the phosphorylation levels were measured using a phosphorylated 
human EGFR (pY1068) Elisa kit following the manufacturer's directions. 
2.2 Results 
2.2.1 Apoptosis enhancement through spherical NP-EGF and the effect of NP size 
The design of NP-EGF used in this study is schematically depicted in Fig. 1a. The NP surface 
was passivated with a self-assembled monolayer of (HS–(CH2)11–(C2H4O)6–COOH, PEG1) 
interspersed with (HS–CH2CH2–(C2H4O)77–N3, PEG2) for the covalent attachment of alkyne 
functionalized EGF through the CuI catalyzed 1,3-dipolar cycloaddition reaction.27,28 We 
included three spherical NP sizes in the size range between 1–100 nm: 21.5 ± 0.9 nm (NP21.5), 
40.4 ± 1.0 nm (NP40.4), and 78.9 ± 1.3 nm (NP78.9). In the initial test experiments we also tested 
98.1 ± 0.8 (NP98.1) particles, but these larger NP lacked sufficient stability when incubated with 
the cells and resulted in unacceptable levels of agglomeration (Fig. 2-1).  
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Fig.  2-1(a) Schematic drawing of the NP-EGF used in this work. PEG1 = HS–(CH2)11–
(C2H4O)6–COOH; PEG2 = HS–CH2CH2–(C2H4O)77–N3. The inset shows SEM images of 
the different NP cores used. The average NP size (± standard deviation) is (clockwise): 
21.5 ± 0.9 nm; 40.4 ± 1.0 nm; 78.9 ± 1.3 nm. (b)–(d) Hydrodynamic diameter (intensity 
statistics) as determined by DLS of citrate capped (b) NP21.5, (c) NP40.4, and (d) NP78.9. (e) 
UV-Vis for NP40.4 before and after functionalization with EGF. (f) Number of EGF bound 
per NP for (left to right): NP78.9-EGF, NP40.4-EGF, NP21.5-EGF. Inset shows ELISA 
calibration standard obtained with free EGF. (g) Zeta-potentials of NP21.5 before (NP21.5-
PEG) and after (NP21.5-EGF) functionalization with EGF. 
 
The SEM images of the NP cores and size distributions as determined by dynamic light 
scattering (DLS, intensity statistics) for NP and NP-EGF are summarized in Fig. 2-1a–d. Fig. 
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1e contains UV-Vis spectra for NP40.4 before and after functionalization with EGF. A small 
systematic red-shift of about 5 nm indicates a change in the local refractive index due to a 
successful loading of the NP with EGF.29,30 The number of EGF ligands per NP was determined 
by ELISA (Fig. 1f). We found that on average 14, 30, 150 EGF were bound to the different NP 
diameters (in the order of increasing diameter), corresponding to an average EGF surface 
density of (8.17 ± 2.64) × 103 μm−2. The zeta-potential increase obtained after cross-linking 
(Fig. 1g) further confirms a successful functionalization of the NP cores with EGF. 
Previous studies have shown that EGF nanoconjugation triggers apoptosis in different cancer 
cell lines (A431, MDA-MB-468, HeLa).25,26 In this study, we focus on the EGFR-
overexpressing MDA-MB-468 breast cancer cell line, which is an established model system for 
investigating the apoptotic efficacy of free EGF.14 We chose a relatively short incubation time 
of 4 h for NP-EGF with the cells in our studies to provide a stringent test of the efficacy of NP-
EGF with different NP core diameters and shapes and to minimize the detrimental effects of 
long colloidal NP incubation times (agglomeration, NP settlement, non-specific binding, etc.). 
The NP were incubated in serum-free DMEM to minimize the corona21,31–33 formation around 
the NP. After 4 h, the NP-EGF containing DMEM was removed and exchanged with fresh 
culture medium. The NP were then incubated for another 20 h before apoptosis was quantified 
by measuring the activity of the activated death protease caspase-3,34,35 which plays a central 
role in the execution of both extrinsic and intrinsic apoptosis.36 The apoptosis enhancement in 
% was calculated from the measured caspase-3 levels ([Casp]) of NP-EGF treated cells and 
untreated control as 100 × ([Casp(treated)] − [Casp(control)])/[Casp(control)]. 
 When characterizing the impact of NP size on NP-EGF induced apoptosis, one needs to 
account for the differences in surface area, and thus the total EGF concentration, for the 
investigated NP diameters. In our experiments we adjusted the NP concentration to keep the 
effective EGF concentration constant at approximately 1.0 nM. We chose this concentration as 
it lies significantly below the threshold required for apoptosis induction by free EGF ligand. 
Unless otherwise noted, we used the following NP concentrations: 128.0 pM (NP21.5), 32.0 pM 
(NP40.4), and 8.0 pM (NP78.9). The stability of NP-EGF under the chosen experimental 
conditions was assayed by UV-Vis and dynamic light scattering (Fig. S2 and S3†). Only NP21.5-
EGF showed some minor self-association, presumably due to the higher particle concentration 
in this case. However, as the contribution from agglomerates was low even in the case of NP21.5-
EGF, all NP preparations were used as prepared. 
In Fig. 2a we summarize the measured apoptosis enhancement (relative to the untreated 
control) for spherical NP-EGF with the investigated core diameters and for the following 
controls: 1 nM and 40 nM free EGF and the supernatant of the last wash for NP78.9-EGF. We 
also performed apoptosis measurements for pegylated NP (NP21.5-PEG, NP40.4-PEG, NP78.9-
PEG) that did not contain any EGF (Fig. 2b). None of the different NP-PEG samples, the free 
EGF samples, or the last wash show any significant apoptosis enhancement. This is different 
for nanoconjugated EGF. NP78.9-EGF achieves a significant (p < 0.0001) increase in the average 
apoptosis enhancement (up to approx. 40%), whereas conjugates with a smaller NP core 
(NP21.5-EGF and NP40.4-EGF) failed to induce apoptosis (no significant change) if the NP 
exposure was limited to 4 h. When comparing the apoptosis levels measured for one effective 
EGF concentration with different NP sizes, the peptide concentration bound to a NP is not 
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necessarily equivalent to that of the free peptide, as all of the peptides bound to one NP 
effectively interact with one or a few receptors to which the NP is bound. We emphasize, 
however, that this effect further increases the “effective” EGF concentration of the smaller NP 
when compared with NP78.9-EGF, making the apoptosis enhancement for NP78.9 even more 
significant. In fact, even greatly increased concentrations of smaller NP-EGF with diameters 
<78.9 nm did not achieve comparable apoptosis levels as observed for 8.0 pM NP78.9-EGF (vide 
infra). 
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Fig.  2-2 (a) Caspase-3 activity (relative to the untreated control) measured after 4 h of 
exposure to (from left to right) NP21.5-EGF, NP40.4-EGF, NP78.9-EGF, NP98.1-EGF, 1 nM 
free EGF, 40 nM free EGF, and the supernatant of the last wash of NP98.1-EGF. The 
effective EGF concentration for the different NP-EGF concentrations was 1.0 nM (see 
text). The plotted data were collected in at least six independent experiments. Error bars 
show standard errors of the mean. Only NP78.9-EGF show a significant increase at a 
significance level of ****p < 0.0001. (b) Caspase-3 activity (relative to the untreated 
control) for pegylated NP (no EGF) as a function of NP core size. NS = not significant. (c) 
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ELISA absorbance signal of phosphorylated EGFR after 15, 30, and 45 min of incubation 
with (from left to right): untreated control, 1 nM free EGF, 40 nM free EGF, NP21.5-EGF, 
NP40.4-EGF, NP78.9-EGF, NR-EGF (AR = 8.6). (d) Apoptosis enhancement as a function 
of NP78.9-EGF concentration in the absence and presence of the RTK inhibitor AG1478 
(250 nM). The effective EGF concentrations are 0.15 nM, 0.30 nM, 0.60 nM, and 1.20 nM. 
*p < 0.05, **p < 0.01. (e) STAT3 phosphorylation for untreated control, 1 nM free EGF, 
and NP78.9-EGF and NP40.4-EGF with an effective EGF concentration of 1 nM (*p < 0.05 
relative to the cell control). (f) Apoptosis enhancement as a function of number of EGF 
peptides bound to NP78.9-EGF. Data in (b) and (f) were collected in three independent 
experiments; data in (c)–(e) were collected from two independent experiments. Error bars 
show standard deviations. 
 
We measured the average EGFR activation as global phosphorylation for NP21.5-EGF, 
NP40.4-EGF, NP78.9-EGF, EGF-conjugated nanorods (NR-EGF) with an aspect ratio of AR = 
8.6, as well as for 1 nM and 40 nM free EGF, and the untreated control 15, 30, and 45 min after 
addition of EGF or its nanoconjugate. The measured phosphorylation levels (Fig. 2c) confirm 
that all EGF nanoconjugates retain the ability to activate EGFR. For NP78.9-EGF, we also 
evaluated EGFR phosphorylation in the presence and absence of an EGFR-selective RTK 
inhibitor (AG1478). In the presence of the inhibitor we observed, as expected, a suppression of 
phosphorylation (Fig. S4†). 
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For NP78.9-EGF we evaluated the apoptosis enhancement for different concentrations in the 
absence and presence of the EGFR-selective RTK inhibitor AG1478 (Fig. 2d). In the absence 
of the inhibitor we observed a systematic increase of apoptosis enhancement as a function of 
increasing concentrations, while the RTK inhibitor suppressed apoptosis for all NP78.9-EGF 
concentrations. The significant difference between the experimental conditions ± AG1478 
confirms that the observed apoptosis is EGFR-dependent. 
The signal and transducer and activator of transcription 3 (STAT3) has been indicated to 
play a major role in initiating apoptosis in response to free EGF.37 Indeed, we found significantly 
enhanced STAT3 phosphorylation levels for nanoconjugated EGF but not for free EGF (Fig. 
2e) after 4 h of NP-EGF exposure, which is consistent with the overall higher apoptotic efficacy 
of NP-EGF when compared with free EGF. We did, however, not detect any significant 
difference in STAT3 activation between NP40.4-EGF and NP78.9-EGF although according to Fig. 
2a the larger NP core has a higher apoptotic efficacy. This finding implies that STAT3 activation 
alone is insufficient to account for the differences observed for nanoconjugated EGF with 
different core sizes, confirming a NP-dependent modulation of the apoptotic efficacy of EGF. 
2.2.2 Effect of EGF surface density on apoptosis enhancement 
Another effect that modifies the apoptotic efficacy of nanoconjugated EGF is multivalency. 
Multivalent presentation of a ligand on a NP leads to increased binding avidities and can 
potentially impact the signaling outcomes. Indeed, we observed that the apoptosis enhancement 
increases with the growing EGF density on the NP. This is exemplified for NP78.9-EGF with 
different EGF densities in Fig. 2f. The measured apoptosis initially increases with the number 
of bound EGF/NP but then converges. For the two highest EGF densities, 140 EGF/NP (≈7.0 × 
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103 μm−2) and 160 EGF/NP (≈8.0 × 103 μm−2), no difference in apoptosis enhancement is 
detected. Unless otherwise noted, we used an average EGF surface density of (7.8 ± 2.3) × 
103 μm−2 with EGF surface densities >6000 μm−2 for all NP sizes throughout this manuscript. 
The NP-EGF lies in the “high” EGF loading regime where the apoptosis enhancement is 
independent of the EGF surface concentration. To account for the potential differences in the 
NP uptake due to different binding affinities related to variations in the number of available 
EGF per particle as well as intrinsic size differences in the uptake mechanism itself, we next 
quantified the uptake of NP-EGF as a function of NP core size. 
2.2.3 Size versus concentration effect 
We first validated that the EGF bound to the NP is available and that the NP-EGF uptake is 
EGF-specific. Fig. 3a shows the dark-field scattering images of MDA-MB-468 cells after 
incubation with NP78.9-EGF (left) and NP78.9-PEG (right). Only the EGF-functionalized NP 
show a systematic binding, indicating that the observed binding is EGF-mediated. We 
quantified the uptake for the EGF- and PEG-functionalized NP of all core sizes by ICP-MS 
(Fig. 3b). For the 1 nM EGF preparations the number of NP per cell increases in the following 
order NP78.9-EGF > NP40.4-EGF > NP21.5-EGF. For all investigated NP sizes the uptake of NP-
EGF was higher than that of NP-PEG, confirming the receptor-mediated uptake of the 
nanoconjugated EGF for all NP sizes.26Selective removal of surface bound NP with mild 
KI/I2 etching38 under conditions that removed all solvent-accessible NP (Fig. S5†) revealed that 
even for the largest NP size at least 50% of the NP were protected from the etchant through 
internalization (labeled NP78.9-EGF-etched in Fig. 3b).  
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Fig.  2-3(a) Darkfield image of MDA-MB-468 cells after incubation with NP78.9-EGF (left) 
and NP78.9-PEG (right) under otherwise identical conditions. Scale bar is 10 μm. (b) 
Average number of particles uptake into MDA-MB-468 cells determined by ICP-MS for 
NP-PEG and NP-EGF with core diameters (left to right) of 21.5 nm, 40.4 nm, 78.9 nm. 
For the NP diameter of 78.9 nm we also included the data obtained after mild KI/I2 etching 
that preferentially removes surface bound NP (“etched”). The effective EGF concentration 
for all conditions was 1 nM, except for NP40.4-EGF*, which contained an effective EGF 
concentration of 1.2 μM. *p < 0.05; **p < 0.01. (c) Average number of EGF molecules 
delivered per cell for (left to right): NP21.5-EGF, NP40.4-EGF, NP78.9-EGF, NP40.4-EGF*. 
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(d) Apoptosis enhancement obtained for NP40.4-EGF*. Data in (b)–(d) were collected from 
at least two independent experiments. 
 
Fig. 3c summarizes the average number of EGF peptides delivered per cell for all NP-EGF 
conjugates with a constant effective EGF concentration of 1 nM. The numbers were generated 
by multiplying the number of delivered NP by the number of bound EGF. Although the number 
of NP taken up decrease with the increasing diameter, the number of delivered EGF molecules 
increases for the different NP cores in the order of NP21.5 < NP40.4 < NP78.9 due to the large 
difference in the bound ligands per particle. 
The stark differences in the number of EGF molecules delivered between different NP sizes 
raise the question whether the high apoptotic efficacy of NP78.9-EGF is related to the physical 
size of the NP78.9 core or whether the higher intracellular concentration of EGF is the dominating 
factor. To address this important question, we measured the apoptosis enhancement for a 
smaller NP core at a greatly increased concentration. We used 400 nM NP40.4-EGF (effective 
EGF concentration 1.2 μM) under otherwise identical conditions as before and obtained 
significantly higher NP uptake (included as NP40.4-EGF* in Fig. 3b). The average number of 
EGF delivered per cell under these conditions (6.1 × 104 EGF per cell) was even higher than for 
NP78.9-EGF (Fig. 3c). However, despite the strongly increased intracellular EGF concentration, 
NP40.4-EGF still failed to result in a measurable apoptosis enhancement (Fig. 3d). This 
observation contradicts a simple EGF (or NP) concentration effect as a cause for the strong 
apoptosis of NP78.9 and, instead, suggests an enhancement mechanism that is more sensitive to 
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the details of the nanoconjugation (size of the NP, ligand density, etc.) than to the number of 
delivered EGF. For instance, it is conceivable that the nanoconjugation has a crucial effect on 
the temporospatial regulation of EGFR signalling. Intriguingly, in cells exposed to free EGF, 
NP21.5-EGF, or NP78.9-EGF (effective EGF concentration was 1 nM in all cases) for 15 min and 
subsequently maintained in a serum-free medium for another 60 min before immunolabelling 
the early endosome marker EEA1, optical microscopy revealed a higher early endosome 
concentration for NP78.9 than for NP21.5 or free EGF (Fig. S6†). Considering that NP21.5-EGF 
achieved comparable or higher intracellular NP concentrations than NP78.9-EGF (Fig. 3b), this 
observation suggests that the NP78.9 core triggers an accumulation of EGF in early endosomes, 
which is consistent with previous tracking studies that showed longer dwell times.26 
2.2.4 NR-EGF fails to enhance apoptosis 
In addition to size, shape is another physical NP property with potential relevance for 
determining the apoptotic efficacy of nanoconjugated EGF. To address the role of AR in EGF-
mediated apoptosis enhancement we synthesized NR with average lengths (AR given in 
parenthesis) of 45.8 ± 5.5 nm (2.5), 60.9 ± 7.3 nm (3.6), 71.6 ± 9.6 nm (5.4), and 88.9 ± 11.0 
nm (8.6) using the seed-mediated method described by Vigderman et al.39 The anisotropic 
growth of NR was achieved with cetyltrimethylammonium bromide (CTAB) as a surface 
ligand. As this ligand is cytotoxic, we exchanged it against benign PEG in a postsynthetic step 
before EGF was introduced through a CuI catalyzed 1,3-dipolar cycloaddition reaction (Fig. 4a–
c). SEM images and UV-Vis spectra of the NR used in this work are provided in Fig. 4d–g. 
Peak extinction wavelengths and zeta-potentials before/after PEGylation as well as the volumes 
and surface areas of the NR used in this work are summarized in Table S1.†  
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Fig.  2-4 (a) Gold NR were functionalized with PEG1 and PEG2 in the presence of 3% v/v 
of Tween 20 to stabilize the NP and to introduce the binding sites for EGF (see text). (b) 
Human EGF was modified with a terminal propargyl residue. (c) The modified EGF was 
tethered to the binding sites of the PEGylated NR through the Cu(I) catalyzed 1,3-dipolar 
cycloaddition reaction. (d)–(g) UV-Vis spectra and SEM images of the nanorods used in 
this work with AR = 2.5, 3.6, 5.4, 8.6. (h) Apoptosis enhancement measured for NR-EGF 
as function of AR under the same experimental conditions as for NP-EGF (1 nM effective 
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EGF concentration, 4 h incubation with rods). (i) Average number of NR-EGF (AR = 8.6) 
per cell after (left) and before (right) KI/I2etching. (j) Relative uptake of (left to right): 
NP78.9-EGF, NP78.9-EGF + amantadine, NP78.9-EGF + nystatin into MDA-MB-468 
determined by ICP-MS. (k) Cellular uptake of (left to right): NR-EGF (AR = 8.6), NR-EGF 
+ amantadine, NR-EGF + nystatin. Data in (h)–(k) were collected from at least two 
independent experiments. Error bars show standard deviations. **p < 0.01; *p < 0.05; NS 
= not significant. 
 
The EGF loadings of the NR were in the order of increasing AR: 23, 58, 101, 160 EGF/NR. 
The average EGF density for all NR was (2.7 ± 2.0) × 104 μm−2. Like before for the spherical 
NP, the NRs were incubated with NR-EGF corresponding to an effective EGF concentration of 
1 nM. All experimental conditions were identical to the spherical NP-EGF studies (4 h 
incubation with NR, followed by 20 h incubation in serum containing medium), but none of the 
investigated AR led to a measurable enhancement in apoptosis (Fig. 4h). This is remarkable, 
considering (i) that the length of the two longest NRs is comparable to the diameter of NP78.9 and 
(ii) that the number of bound EGF for the highest AR even slightly exceeds that of NP78.9-EGF. 
Differences in the uptake behavior between NR and NP have recently attracted a lot of interest. 
It was observed that high AR NRs are taken up much more slowly than spherical NP.40,41 We 
confirmed that the high AR NR-EGF used in this work were still taken up by comparing the 
cellular gold content before and after removing the solvent-accessible gold NR with 
KI/I2 etchant through ICP-MS (Fig. 4i). The large fraction of protected NR observed in these 
40 
 
experiments confirms their intracellular uptake. However, the NR uptake, especially for high 
AR NR, does not necessarily occur along the same pathway as that of spherical NP.42,43 This is 
relevant as shape-dependent differences in the uptake mechanisms can lead to different 
intracellular NP-EGF distributions.44–46 
To verify the differences in the uptake of spherical NP78.9-EGF and high AR NR-EGF (AR 
= 8.6), we performed uptake inhibition assays for clathrin- and caveolae-mediated endocytosis 
(Fig. 4j and k). We measured the cellular gold content though ICP-MS for the cells treated with 
nystatin as an inhibitor for caveolae-mediated endocytosis or amantadine as an inhibitor for 
clathrin-mediated endocytosis. The inhibition studies reveal that the NP78.9-EGF uptake (Fig. 
4j) is reduced through adamantine but not by nystatin, as expected for clathrin-mediated uptake. 
In contrast, for NR-EGF adamantine does not affect the uptake (Fig. 4k). Instead, we observe a 
reduction in uptake after nystatin treatment, indicative of caveolae-mediated endocytosis. 
Positive controls for the inhibitors are provided in Fig. S7.† 
2.2.5 NP78.9-EGF induced oxidative stress 
Oxidative stress plays a central role in apoptosis, with relevance to both induction as well as 
execution. Although oxidative stress is often indicated in NP-induced apoptosis,47–49 there are 
different mechanisms of ROS formation and the generated ROS can have different functions. 
Depending on the chemical composition of the NP and its ligands, NP and ligands may create 
ROS through redox reactions. Inert NP can trigger cellular responses that result in the ROS 
formation. For gold50,51 and silver NP,52,53as well as for many metal–oxide NP,54,55 ROS 
generation has been observed as a consequence of mitochondrial damage that results in 
apoptosis.56 For the biofunctionalized NP, as for the NP investigated in this work, the 
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mechanism of ROS generation is furthermore expected to depend on the interplay between the 
ligand, NP, and cell receptor. Relevant in this context is that EGFR activation triggers ROS 
formation as signaling molecules, and H2O2, in particular, has been indicated in the receptor 
transactivation.57–60 
As a first step towards a quantitative understanding of the relationship between EGF 
nanoconjugation and oxidative stress, we measured both cytoplasmic ROS and mitochondrial 
superoxide levels after the addition of NP78.9-EGF. Fig. 5a summarizes the cytoplasmic ROS 
levels after NP78.9-EGF incubation with MDA-MB-468 cells for 4 h, and Fig. 5b shows 
cytoplasmic ROS levels after maintaining the cells for an additional 20 h after removal of NP78.9-
EGF. Several controls were included: untreated, treatment with tert-butyl hydroperoxide 
(TBHP), and NP-EGF in the presence of NAC. Importantly, for both the investigated time 
points, NP78.9-EGF was found to induce a strong increase in cytoplasmic ROS concentration 
that was almost identical to that obtained with the positive control, TBHP. The ROS levels for 
NP78.9-EGF significantly exceeded those of free EGF at the same effective concentration (1 nM 
ligand). In Fig. 5b we also included the ROS levels for NP78.9-PEG obtained under the otherwise 
identical conditions. The ROS levels for the latter were even lower than those of free EGF. The 
increased ROS levels for NP78.9-EGF result from the synergistic interactions between the NP 
core and conjugated EGF. 
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Fig.  2-5(a) Quantification of ROS levels through fluorescence flow cytometry using a 
CellRox assay. Fluorescence histogram for the untreated control, TBHP positive control, 
NP78.9-EGF + NAC (NAC), and NP78.9-EGF are included. (b) The same data as in (a) but 
after additional culturing for 20 h after removal of NP78.9-EGF. NP78.9-PEG was included 
as an additional control. (c) Quantification of mitochondrial ROS under the same 
conditions as in (a). (d) JC1 mitochondrial membrane potential assay. NP78.9-EGF does 
not result in a measurable reduction in fluorescence intensity relative to the untreated 
control, indicating the intact mitochondrial membranes. FCCP = carbonyl cyanide 4-
(trifluoromethoxy) phenylhydrazone is a positive control that reduces the mitochondrial 
potential. 
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We monitored the mitochondrial superoxide (O2−) concentration as the primary ROS 
generated in the mitochondria. Fig. 5cshows the mitochondrial superoxide concentrations for 
cells incubated for 4 h with NP78.9-EGF and maintained for an additional 20 h in the incubator 
after the removal of NP78.9-EGF as well as for the positive and negative controls. No significant 
increase in mitochondrial superoxide concentration was detected after NP78.9-EGF treatment. 
We also did not detect any decrease in mitochondrial membrane potential (Fig. 5d). Overall, the 
data in Fig. 5a–d show that NP78.9-EGF results in a significant increase in cytoplasmic ROS, but 
that the effect on mitochondrial ROS and membrane integrity is negligible. 
2.2.6 NP78.9-EGF impact on intracellular glutathione homeostasis and its effect on apoptosis 
GSH is a major thiol-based redox buffer that in healthy cells is present in high concentrations 
in its reduced state and that is converted into its oxidized dimer state GSSG through reaction 
with ROS.61,62 Importantly, the cellular GSH content is indicated to play a direct role in the 
induction and regulation of apoptosis.63,64Fig. 6a shows the cellular GSH/GSSG concentration 
ratio for NP78.9-EGF, NP40.4-EGF, NP21.5-EGF, and NP78.9-EGF in the presence of the EGFR-
selective RTK inhibitor AG1478, and the anti-oxidants NAC (N-actylcysteine), trolox (6-
hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid), or tempol (4-hydroxy-2,2,6,6-
tetramethylpiperidin-1-oxyl). In agreement with the size-dependence of the EGF 
nanoconjugation induced apoptosis, we found that the drop in GSH/GSSG ratio was specific to 
the NP78.9 core; smaller NP cores did not induce a significant reduction in the GSH/GSSG ratio 
under the chosen experimental conditions. Importantly, the presence of the EGFR-specific RTK 
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inhibitor AG1478, or of the antioxidants NAC, trolox or tempol mitigated the oxidative stress 
induced by NP78.9-EGF and prevented a significant drop in the GSH/GSSG ratio.  
 
Fig.  2-6(a) GSH/GSSG ratio for the untreated control, NP78.9-EGF, NP40.4-EGF NP21.5-
EGF, NP78.9-EGF + AG1478, NP78.9-EGF + NAC, NP78.9-EGF + trolox, NP78.9-EGF + 
tempol. (b) Apoptosis enhancement for NP78.9-EGF, NP78.9-EGF + AG1478, NP78.9-EGF 
+ trolox, NP78.9-EGF + tempol. All presented data were recorded from three independent 
experiments. Error bars show standard deviations. Significance was evaluated relative to 
the untreated control (a) or NP78.9-EGF (b). **p < 0.01; *p < 0.05. 
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When we measured the apoptosis enhancement for NP78.9-EGF in the presence of the EGFR 
inhibitor or the three antioxidants (Fig. 6b), we found that the inhibition of EGFR 
phosphorylation through AG1478 and the reduction of oxidative stress through NAC or tempol 
very efficiently suppressed apoptosis. Surprisingly, the antioxidant trolox did not suppress the 
apoptotic efficacy of NP78.9-EGF, instead an even higher apoptosis enhancement was detected 
for the combination of NP78.9-EGF and trolox. We verified in control experiments that trolox 
alone did not induce apoptosis under the chosen experimental conditions (Fig. S8†), confirming 
that the detected gain in apoptosis enhancement resulted from a synergistic effect between 
NP78.9-EGF and trolox. A potential explanation for the different effects of trolox and NAC or 
tempol could be related to the different chemical natures of the antioxidants. Different from the 
GSH precursor NAC that removes ROS by enhancing the glutathione response,65 or the stable 
radical tempol whose primary reaction product after reaction with ROS is an oxoammonium 
cation,66,67 trolox is converted into a reactive radical cation by reacting with ROS. The observed 
failure of trolox to inhibit apoptosis could, therefore, be caused by the radical nature of the 
reaction product. The trolox radical cation is a strong oxidant and its reactivity could result in 
cellular damage and other detrimental cell processes. The apoptotic effect may be further 
potentiated by the preferential localization of this vitamin D derivative to cellular membranes. 
2.3 Discussion 
The systematic analysis of NP-EGF induced apoptosis in Fig. 2 confirms that neither EGF 
ligand nor NP by itself results in apoptosis under the chosen experimental conditions. The 
observed apoptosis must, therefore, be a result of the conjugation of EGF to NP and the 
accompanying changes in the cellular response to the ligand and core. The EGF surface density, 
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NP size, and shape all interact to influence the apoptotic efficacy of nanoconjugated EGF. High 
EGF densities favor apoptosis, spherical NP are more effective than NR, and the largest NP 
investigated in this work with a diameter of 80 nm are particularly effective. NP-EGF with 
smaller core diameters can also induce apoptosis, but require longer co-incubation times than 
the 4 h applied in this work.25 All of the investigated EGF nanoconjugates activate EGFR. Even 
though the effective EGF concentration was constant in all cases, the measured phosphorylation 
differs between the nanoconjugates (Fig. 2c). NP78.9-EGF and NR-EGF (AR = 8.6) show higher 
phosphorylation levels than NP21.5-EGF and NP40.4-EGF. In fact, NP78.9-EGF and NR-EGF 
achieve similar phosphorylation levels to 40 nM free EGF, although the effective EGF 
concentration of the nanoconjugates is only 1 nM. But despite the similar phosphorylation levels 
for free EGF (40 nM), NP78.9-EGF, and NR-EGF, only NP78.9-EGF effectively induced 
apoptosis (Fig. 2a). The observation that comparable EGFR phosphorylation levels yield 
different apoptosis enhancements implies that the total EGFR activation alone is insufficient to 
account for the observed apoptosis differences under the chosen experimental conditions. 
Instead, differences in the activation process that are related to the structure and ligand 
presentation by EGF-presenting NP seem to play a key role in the induction of apoptosis. For 
one, the increase in apoptosis with increasing EGF surface density in Fig. 2f confirms that 
multivalent EGF presentation enhances the apoptotic signaling. But the shape of the NP also 
plays an important role. For instance, NR-EGF (AR = 8.6) with comparable EGF surface 
loadings and total phosphorylation levels to NP78.9-EGF did not induce apoptosis (Fig. 4h). We 
conclude that an accurate evaluation of apoptotic efficacy requires an explicit consideration of 
NP size, ligand density, and shape. 
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Based on the putative mechanism for free EGF induced apoptosis enhancement, which 
attributes apoptosis to the accumulation of activated EGFR in early endosomes,12,13,15,68 it is 
conceivable that it is not the global EGFR signaling but specifically the endosomal EGFR 
signaling that is the determining factor for NP-EGF induced apoptosis enhancement. Apoptosis 
could then be the result of EGF nanoconjugation induced changes in the temporospatial 
intracellular signaling patterns of the bound EGFR. The fact that NP40.4-EGF failed to induce 
comparable apoptosis levels to NP78.9-EGF, even when the concentration of delivered EGF was 
much higher (Fig. 3b–d) emphasizes a central role of the physical NP size in determining the 
apoptotic efficacy of nanoconjugated EGF. The shape and size of a stiff NP have direct 
implications for the trafficking of NP-EGF tethered EGFR as vesicle sorting and trafficking 
require a high degree of structural flexibility, or pleomorphism, of the participating vesicles in 
the dense matrix of the cytoplasm.69 Gold NP are hard, and under typical cellular conditions 
they are non-deformable objects. The structural flexibility of a vesicle of a given size (for 
instance formed through clathrin-mediated endocytosis) and, thus, its mobility in the cytoplasm 
are expected to decrease with the increasing size of the contained gold NP cargo.70 Indeed, we 
observed higher early endosome concentrations for NP78.9-EGF than for NP21.5-EGF (Fig. S6†), 
which could result from an overall slower intracellular trafficking of the larger NP 
core.26 Confocal scans also indicated some differences in the spatial distribution of EEA1 for 
NP78.9-EGF, which motivate further detailed experimental investigation of the impact of NP size 
on the trafficking of nanoconjugated EGF. 
EGFR activation is known to trigger ROS generation,57,71 and the increase in cytoplasmic 
ROS and reduction of the cellular GSH/GSSG ratio observed in this work are consistent with a 
48 
 
persistent activation of cytoplasmic EGFR. The associated change in the cellular milieu 
represents a key checkpoint in EGF nanoconjugation induced apoptosis. Suppression of a drop 
in GSH/GSSG ratio by NAC or tempol, or inhibition of EGFR signaling through AG1478 
successfully prevented NP-EGF induced apoptosis (Fig. 6). Intriguingly, the nanoconjugated 
EGF did not trigger increased mitochondrial ROS levels, which corroborates the hypothesis that 
mitochondria-independent redox signaling in the cytoplasm is the origin of EGF 
nanoconjugation induced apoptosis. 
For ligand–receptor pairs whose signaling outcomes are spatially regulated, differences in 
the uptake mechanism can result in different signaling results. Importantly, for NR-EGF (AR = 
8.6) we found indications of caveolae-mediated endocytosis, whereas NP78.9-EGF was primarily 
taken up by clathrin-mediated endocytosis (Fig. 4j and k). A switch in the uptake mechanism 
from clathrin- to caveolae-mediated endocytosis for nanorods with a length of around 80 nm is 
in good agreement with the previous findings by Liu et al.42 A transition from clathrin- to 
caveolae-mediated uptake changes the temporospatial distribution of the nanoconjugated EGF 
(and the bound EGFR). In addition, caveolin-1, which is a component of caveolae, can 
downregulate the EGFR signaling by dephosphorylating the receptor tyrosine kinase.72–74 We, 
consequently, attribute the observed differences in the apoptotic efficacy of high AR NR and 
larger NP to a reduction of oxidative stress due to shape-dependent differences in the uptake 
and intracellular signaling of EGFR. Additional studies into the cellular mechanisms underlying 
the shape-dependent differences in oxidative stress upon the uptake of nanoconjugated EGF are 
warranted. 
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2.4 Conclusion 
NP–cell interactions are complex and can result in unexpected and potentially harmful signaling 
outcomes for nanoconjugated ligands targeted at cell surface receptors. If these interactions are 
understood in detail, they provide, however, also new opportunities for manipulating and 
controlling cell signaling. In this work, we have demonstrated that nanoconjugation modulates 
the apoptotic efficacy of EGF and that the magnitude of the effect depends not only on the ligand 
density of the NP but, in particular, on the size and shape of the NP core. Under the chosen 
experimental conditions, NP78.9-EGF was much more efficient in inducing apoptosis than 
smaller NP or high AR NR with comparable EGF loading. Apoptosis was shown to be related 
to NP78.9-EGF induced oxidative stress. Cytoplasmic ROS generation and perturbation of the 
glutathione homeostasis were key events for EGF nanoconjugation mediated apoptosis and their 
abrogation prevented apoptosis. The successful induction of apoptosis in cancer cells through 
nanoconjugated EGF is particularly important and has translational potential as apoptosis 
evasion is one of the hallmarks of cancer and the established EGFR targeted therapeutics suffer 
from rapid development of resistance.75 
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3 Chapter 3 
Epidermal Growth Factor Presenting Polymer Nanoparticles Stimulate Nitric Oxide 
Generation and Modulate Apoptotic Signaling through Nitrosylation of JNK 
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3.1 Introduction 
Epidermal growth factor (EGF) is usually associated with cell growth and proliferation but 
it has long been known that under certain conditions EGF binding to its receptor (EGFR) 
can also induce apoptosis.1-3 Intriguingly, it was found that conjugation of EGF to a 
nanoparticle (NP) enhances EGF-induced apoptosis, as indicated by increased caspase-3 
activity, nucleus condensation, phosphatidylserine translocation and changes in cell 
morphology.4-6 The data available so far suggest that the NP-EGF-induced apoptosis arises 
from a perturbation of the spatial regulation of EGFR signaling due to an accumulation of 
activated EGFR in early endosomes. This behavior is consistent with studies on “free” EGF 
that have shown that accumulation of activated EGFR in early endosomes is a key factor 
for apoptosis induced by EGF.7-10 The intracellular mechanisms that couple spatial 
dysregulation of activated EGFR upon NP-EGF binding to apoptosis remain, however, 
incompletely understood. Initial studies on nanoconjugated EGF have shown that increased 
levels of reactive oxygen species (ROS) are an important factor in NP-EGF-mediated 
apoptosis.6 The observation of an increase in ROS after NP-EGF binding and uptake raises 
important questions as to whether reactive nitrogen species (RNS), in particular nitric oxide 
(NO), are also increased after NP-EGF binding and what role NP-EGF-induced NO plays 
in the induction of apoptosis. Characterizing the role of the small, lipophilic molecule NO 
in NP-EGF-induced apoptosis is of great interest as NO has important biological regulatory 
functions with direct relevance to apoptosis.  
NO is a reactive and volatile small molecule that is regulated by control of its synthesis 
through nitric oxide synthases (NOS). Importantly, previous studies have revealed that 
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EGF can activate inducible NOS and trigger increased NO levels.11-13 If present in small 
quantities, NO represents a signaling molecule that functions as a second messenger.14 
Regulatory functions of NO derive from the molecule’s general redox-reactivity, for 
instance, in the nitrosylation of thiols in kinases and caspases and other enzymes, as well 
as from its specific recognition through NO receptors.15-19 The diffusion length and, thus, 
the radius of activity of an individual NO molecule is limited through its reactivity and the 
associated “reactive quenching”. In fact, if NO is present at high concentrations, off-target 
NO-driven redox reactions can cause significant cellular damage. The role of NO in cancer 
is complex20 and the molecule has been observed – depending on its concentration – either 
to promote proliferation, enhance invasiveness and metastasis, and repress apoptosis or to 
induce oxidative stress and trigger apoptosis.21-24 Interestingly, NO is particularly relevant 
for the disease progression in the BLBC subtype which primarily display a triple negative 
(ER-, PR- and HER2-) phenotype accounting for 15% of all breast cancers.17,25-32 BLBC 
has poor prognosis and remains difficult to treat 33,34 and, therefore, there is an urgent need 
for development of new robust cancer inactivation strategies. Since some BLBCs express 
EGFR,35 NP-EGF-induced apoptosis could pave the path to a potential strategy to target 
this subset of cancers, provided the mechanisms of NP-EGF-induced apoptosis and the 
interplay of ROS and NO are understood in greater detail.  
In the current study, we investigate how the nanoconjugation of EGF affects intracellular 
NO levels in an EGFR-overexpressing BLBC cell model (MDA-MB-468), in BLBC cells 
with medium EGFR expression levels (MDA-MB-231), and in Her2+ control cells 
(SKBR3) with low EGFR expression levels and establish a correlation between NO levels 
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and NP-EGF-induced apoptosis, as measured by caspase-3 activity.36 As NO has been 
reported to have both pro-apoptotic as well as cell-protective functions, we monitored the 
effect of NP-EGF on apoptosis both in the presence and absence of NO scavenger.  
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3.2 Methods 
3.2.1 PLGA-lipid-EGF NP (NP-EGF) synthesis and functionalization.  
      The NP preparation followed the method described by Mandal et al37 optimized by 
Behnaz Eshaghi. 2.5 mg of PLGA powder (lactide:glycolide 50:50, Mw = 24,000-38,000) 
was dissolved in 1 mL of anhydrous acetonitrile to prepare the polymer solution. 8 µL of 
25 mg/mL 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[azido(polyethylene 
glycol)-2000] (ammonium salt)  (DSPE-PEG(2000)-azide) and 5 µL of 16:0 1,2-
dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) 
(ammonium salt) (Liss Rhod PE) were added to 4 mL of MilliQ water (18 MΩcm). 400 
µL of PLGA solution was added dropwise to the lipid-water mixture and the mixture was 
sonicated for 5 min at room temperature followed by a brief vortexing to homogenize the 
synthesized PLGA-lipid NP dispersion. The NP dispersion was then washed twice by 
centrifugation using 4mL 10K Nominal Molecular Weight Limit (NMWL) Amicon® 
Ultra-4 Centrifugal Filters. 2 μL of a 100 mg/mL propargyl-N-hydroxysuccinimidylester 
(C10H11NO5) solution in DMSO was added to 100 µL of 1mg/mL EGF and incubated on 
ice for 6 h. The mixture was dialyzed against 1x PBS for 72 h. 150 μL PLGA-lipid NP 
dispersion was then incubated overnight with 25 μL of the prepared functionalized EGF at 
4oC in 500 μM ascorbic acid and 100 μM CuSO4 (catalyst for the cycloaddition reaction) 
containing buffer. The resulting NP-EGF was then washed twice by centrifugal filters prior 
to resuspension in DMEM. 
3.2.2 NP surface EGF quantification.  
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      The amount of NP-loaded EGF was quantified using a EGF Human ELISA Kit 
(Invitrogen). Briefly, NPs were diluted to reach a concentration of 2 pM and then incubated 
in an antibody-coated 96-well plate provided in the kit. Total EGF concentrations in the 
samples were determined following the protocol provided by the vendor. The number of 
EGF per NP were then calculated. The EGF concentration in the supernatant of the NP 
samples after the last wash was also quantified to detect any possible undesired free EGF 
in the NP samples.  
3.2.3 Caspase-3 activity measurements.  
      MDA-MB-468, MDA-MB-231, and SKBR3 cells were cultured in 6-well plates in 
DMEM-10% FBS at a density of 1*105/mL. After 80% confluency was reached, the cell 
medium was removed and replaced with fresh DMEM containing NP samples or controls. 
The plate was incubated for 4 h at 37oC in the presence of 5% CO2. Cells were then washed 
3x with Hank’s buffer and incubated for additional 20 h in DMEM-10% FBS at 37oC in 
the presence of CO2. Cells were collected by trypsinization and washed with 1x PBS by 
centrifugation. EnzChek® Caspase-3 Assay Kit was used to quantify caspase-3 activity in 
the samples. Total protein concentration in samples were also quantified using Pierce BCA 
Protein Assay Kit to account for the differences in the sample size. Apoptosis enhancement 
relative to the control cell samples with no treatment were calculated based on the caspase-
3 activity levels.  
3.2.4 Quantification of NP cellular uptake.  
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      After 4 h of incubation of NPs with cells in DMEM (NP concentration: 100 pM), cells 
were washed with 1x PBS and the cell density was quantified using a hemacytometer. After 
lysing of the cells, the sample fluorescence was quantified in a 96-well plate using a 
SpectraMax M5 plate reader. Known concentrations of NPs were used as the standard 
curve to calculate NP concentration in the lysate. The number of NPs per cell was then 
calculated based on the total number of NPs and total number of cells in the sample. 
3.2.5 ROS quantification.  
      Cytoplasmic ROS was quantified using a CellROX Deep Red Flow Cytometry Assay 
Kit (Invitrogen). Briefly, cells were incubated with desired samples with DMEM for 4 hrs. 
Following cells incubation with fluorogenic CellROX™ Deep Red Reagent, cells were 
trypsinized and washed with 1X PBS and analyzed with flow cytometry for fluorescence 
quantification.  
3.2.6 Nitric Oxide quantification.  
      Cellular NO levels were quantified using a Nitric Oxide Assay Kit (Invitrogen™). 
After 4 h of incubation, the cells were detached, washed with 1x PBS, and lysed before NO 
quantification.  
3.2.7 Western Blot.  
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Cells were incubated with desired samples and controls for 4 h, detached, washed with 1x 
PBS, and lysed with cell extraction buffer (Invitrogen™). Total protein concentrations 
were quantified using Bio-Rad Protein Assay Dye Reagent Concentrate. All samples were 
diluted to the concentration of the sample with the lowest concentration before gel 
electrophoresis. Samples were mixed with NuPAGE lithium dodecyl sulfate (LDS) sample 
buffer and NuPAGE sample reducing agent and then incubated at 70oC for 10 min. Samples 
were loaded in NuPAGE 4-12% Bis-Tris gels and run at 100 V for 2 h at room temperature 
followed by transfer to a membrane at 4oC for overnight. Membranes were blocked in tris-
buffered saline and polysorbate 20 (TBST)-5% non-fat dry milk (NFDM) for 30 min 
followed by primary antibody incubation overnight at 4oC. The membrane was washed 3x 
with TBST and incubated with peroxidase-conjugated secondary antibody for 30 min. 
Membrane was washed 3x with TBST and incubated for 30 s in chemiluminescent 
substrate, and was finally imaged using a BioRAD ChemiDoc™ XRS+ System.  
3.2.8 Detection of protein S-Nitrosylation.  
      Cells were incubated with desired samples and controls for 4 h, detached, and washed 
with 1x PBS. Protein S-Nitrosylation was detected using Pierce™ S-Nitrosylation Western 
Blot Kit. Briefly, samples were lysed by HENS buffer (100 mM HEPES (pH 7.8), 1 mM 
EDTA, 0.1 mM neocuproine, and 1% SDS) provided in the kit, labeled by iodoacetyl 
tandem mass tag (iodoTMT) Reagent, and detected by anti-TMT antibody through Western 
Blotting.  
3.2.9 Inhibitors and Scavengers.  
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      AG1478, an EGFR-specific RTK inhibitor,38 was used at a concentration of 500 nM. 
AG1478 was initially dissolved in DMSO and then diluted to the final concentration in 
DMEM. SP600125 JNK inhibitor39 was used at a concentration of 25 µM. Carboxy-
PTIO,40 a selective NO scavenger, was used at a concentration of 1 mM during the initial 
4 h of NP treatment and then at a concentration of 100 µM for the subsequent 20 h 
incubation after NP removal.  
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3.3 Results and Discussion 
NP-EGF with Polymer Core Trigger Apoptosis in EGFR-overexpressing BLBC Cell 
Line. We used the lipid-wrapped poly(lactic-co-glycolic acid), PLGA, NPs schematically 
outlined in Figure 1a as platform to create NP-EGF of defined size and surface loading. 
The biodegradable PLGA core represents a scaffold with defined size, and the biomimetic 
membrane layer provides control over the surface properties of the NPs and facilitates the 
integration of azide-modified lipids to covalently tether alkyne-modified EGF through the 
Cu(I)-catalyzed 1,3-dipolar cycloaddition41. The lipid layer was composed of fluorescent 
16:0 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B 
sulfonyl) (ammonium salt), referred to in the following as Liss Rhod PE, and 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[azido(polyethylene glycol)-2000] 
(ammonium salt), in the following referred to as  DSPE-PEG2000-N3, in the ratio 5:95. 
Figure 1b shows the hydrodynamic diameter determined by dynamic light scattering 
(DLS) for PLGA NP preparations before and after wrapping the core in a lipid-PEG layer; 
an increase in average diameter from 80  4 nm to 88  4 nm is observed. The zeta potential 
of the NPs was -28.5 mV and -22.5 mV before and after membrane wrapping. Binding of 
EGF to the NPs further increased the hydrodynamic diameter to approx. 100 nm. The 
number of EGF peptides bound per NP was determined by ELISA to be 64 ± 6 (Figure 
1c). The supernatant did not show any residual EGF, ensuring that all cellular effects are 
exclusively caused by nanoconjugated EGF. Unless otherwise noted we used NP-EGF with 
a hydrodynamic diameter of approx. 90 nm and effective EGF concentration of approx. 6 
nM throughout this work. 
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Since previous studies demonstrating enhanced, EGF-induced apoptosis upon 
nanoconjugation were all performed with gold NPs4-6, we first verified that the softer, 
biodegradable polymer NPs also induce apoptosis. We tested the apoptotic effect of the 
EGF-loaded NPs (NP-EGF) in vitro with the EGFR overexpressing BLBC in vitro cell 
model, MDA-MB-468. NP-EGF binding and uptake in these cells was EGF-specific 
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Fig.  3-1 a) Scheme of NP EGF-functionalized NPs (NP-EGF). b) Hydrodynamic 
diameter distribution (left) and zeta potential (right) of PLGA NPs before and after 
wrapping with lipid-PEG layer. Inset shows the calculated difference between NP 
size distributions recorded after and before wrapping with lipid-PEG layer. c) 
Number of EGF per NP quantified by ELISA. d,e) Uptake of NP-EGF after 4 hours 
incubation in DMEM as function of input concentration determined by FACS. f) 
Apoptosis enhancement of PLGA-EGF after 24 h (4h NP incubation + 20 h post-
incubation after excess NP removal) as a function of NP input. g) Apoptosis 
enhancement induced by 100 pM PLGA-EGF and PLA-EGF (4h NP incubation + 20 
h post-incubation after excess NP removal). h) Apoptosis enhancement induced by 
different sizes of PLGA-EGF (100 pM). 
 
(Figure 1d) and concentration dependent (Figure 1e). After an initial steep increase of 
uptake as function of concentration, the increase in uptake levels off for concentrations ≥ 
100 pM, indicative of a saturation of uptake.  
To quantify the apoptotic effect of the NPs, we incubated MDA-MB-468 cells with NP-
EGF concentrations of 8 pM, 20 pM, 50 pM, 100 pM for 4h. The NP solution was then 
removed and the cells were maintained in cell medium at 37˚C for another 20 h before 
caspase-3 levels were quantified and apoptosis enhancements in % relative to the no 
treatment control were calculated. Consistent with the trends for NP-EGF uptake we 
detected an increase in apoptosis with increasing NP-EGF input (Figure 1f). For a NP-
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EGF input concentration of 100 pM (effective EGF concentration 6 nM), we reliably 
measured an average apoptosis enhancement (relative to the no treatment control) of 
approximately 58% in EGFR overexpressing MDA-MB-468. We did not detect increased 
apoptosis levels for NP-EGF in the BLBC cell line with low EGFR expression level 
(MDA-MB-231) or luminal cells (SKBR3) under the same experimental conditions (vide 
infra). However, the strongly EGFR over-expressing epidermoid carcinoma cell line A431 
also showed greatly increased levels of apoptosis (Figure S1), suggesting that the 
apoptosis-enhancing effect is common in other EGFR-overexpressing cancer cells. In a 
second set of experiments we replaced PLGA with polylactic acid (PLA) as core material 
and observed similar levels of apoptosis enhancement in MDA-MB-468 (Figure 1g), 
confirming that the apoptotic effect is largely independent of the choice of the polymer 
core material. 
The maximum apoptosis enhancement for the polymeric NPs investigated in this work are 
comparable with the maximum apoptosis enhancements observed previously for EGF-
presenting 80 nm gold NPs.4-6 It must be emphasized, however, that the gold NPs achieved 
this effect at a much lower input concentration. An 8 pM solution of gold NP-EGF was 
sufficient to yield the same maximum phosphorylation as a 100 pM solution of polymeric 
(PLGA, PLA) NP-EGF. In contrast, an 8 pM solution of polymeric NP-EGF did not show 
any significant increase in apoptosis. The polymer NPs used in this work had glass 
transition temperatures lower than 37C and were, thus, quite soft. The difference in 
apoptotic efficacy between metal and polymer core NP-EGF may be related to differences 
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in the core stiffness (polymer vs. metal), which can change the intracellular trafficking42-47 
and, thus, affect the spatial regulation of EGFR signaling. Alternatively, the effect could 
also be due to differences in the uptake of NPs with different densities (gold versus 
polymer) in the cell-culture based approaches. A further analysis of the NP core specific 
differences is ongoing but goes beyond the scope of this work. The key finding of this 
section is that EGF-presenting polymer NPs can induce apoptosis in EGFR overexpressing  
 
Fig.  3-2 a) Cellular ROS levels of MDA-MB-468 cells measured using the CellRox 
indicator by FACS. The effect of EGF-functionalized PLGA NP (90 nm diameter, 100 pM 
input concentrations) with and without NO scavenger (Carboxy-PTIO) (1 mM) and EGFR-
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specific RTK inhibitor AG1478 (500 nM) was quantified. A no-treatment control was 
included as reference. b) Cellular ROS levels of MDA-MB-231 cells and c) SKBR3 cells 
after 4 h of incubation. d) Intracellular NO levels as determined by nitric oxide assay 
(Invitrogen™) for MDA-MB-468. Data are averages over two independent repeats. 
 
BLBC cells. Even if polymer NPs require higher concentrations than metallic NPs, they 
offer the advantages of biodegradability and higher general biocompatibility. 
We evaluated the dependence of the apoptotic effect on the size of the NP samples by 
measuring the apoptosis obtained with PLGA NP-EGF with average hydrodynamic 
diameters of 76  4 nm, 102  5  nm, and 124  6 nm at a constant NP input concentration 
of 100 pM (Figure 1h). We found that the NPs with intermediate size provided the 
strongest enhancement of apoptosis.  
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3.3.1 NP-EGF-Induced Reactive Oxygen Species (ROS) and NO Formation.  
      Induced oxidative stress is an important factor in NP-associated toxicity,48-50 and it is 
also known to play a role in the apoptosis observed for NP-EGF with gold core.6 We 
measured the general cellular oxidative stress (defined by hydroxyl radicals, superoxides, 
peroxynitrites, NO) in response to PLGA NP-EGF (100 pM) and for the same NPs in the 
presence of the EGFR-specific kinase inhibitor AG147838, or NO scavenger Carboxy-
PTIO51 using a fluorescence (CellRox) indicator for MDA-MB-468 (Figure 2a), MDA-
MB-231 (Figure 2b), and SKBR3 (Figure 2c) cells. No-treatment controls and controls 
with AG1478 or Carboxy-PTIO in the absence of NP-EGF were included in all our 
measurements.  
For MDA-MB-468 (Figure 2a) we found that NP-EGF addition induces significant levels 
of oxidative stress but that both AG1478 and the NO-specific scavenger Carboxy-PTIO 
reduce this stress. Interestingly, while AG1478 lowers the oxidative stress to the cellular 
background of the no-treatment controls, the NO scavenger reduced the oxidative stress 
even below the levels of the no-treatment control. Together, these findings imply i.) that 
NP-EGF-induced oxidative stress in MDA-MB-468 is EGFR-dependent, ii.) that NO 
contributes significantly to the measured oxidative stress, and iii.) that the intracellular NO 
levels are already non-negligible even in the absence of any NP challenge. In MDA-MB-
231 (Figure 2b) AG1478 inhibitor and NO scavenger both trigger an increase in oxidative 
stress, but the total oxidative stress observed for NP-EGF is essentially identical to the no 
treatment control. In SKBR3 (Figure 2c), NP-EGF addition even reduces the oxidative 
stress relative to the no treatment control. NO scavenger and AG1478 (in the presence of 
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the NP-EGF) increase oxidative stress, while AG1478 alone achieves a strong reduction. 
In conclusion, for the chosen NP-EGF concentrations (100 pM) and exposure times (4 h) 
only the EGFR overexpressing BLBC model MDA-MB-468 exhibits a NP-EGF-induced 
increase in ROS levels that is reversed by NO scavenger. The striking differences in the 
effect of AG1478 and NO scavenger on the oxidative stress in the different cell lines 
underlines the complex, cell-specific regulation of ROS and NO generation. 
To further characterize the contribution of NO to the detected oxidative stress in MDA-
MB-468, we measured the intracellular NO levels with a dedicated NO assay (Figure 2d). 
This essay confirmed significantly increased levels of NO after addition of NP-EGF. NO 
scavenger and AG1478 both successfully inhibited an increase in intracellular NO in 
response to NP-EGF. These finding provide experimental evidence that the increase in 
intracellular NO is related to the activation of EGFR. We also measured the NO levels 
obtained for a 40 nM solution of free EGF, corresponding to a > 6-fold higher effective 
EGF concentration than in the case of NP-EGF. Despite the higher EGF concentration, the 
measured NO levels were lower for free EGF. We conclude that NP-EGF is particularly 
effective in inducing apoptosis. 
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3.3.2 Effect of NO Scavenger on NP-EGF-Induced Apoptosis. The published literature 
suggests that the effect of NO on cancer cells is concentration-dependent.16,52 While 
low concentrations < 100 nM generally favor proliferation and metastasis, higher 
concentrations > 400 nM can cause cytotoxicity and apoptosis.20,53,54 In the absence 
of NO scavenger we observed an apoptosis enhancement of up to ~58% in MDA-
MB-468 but noted no increase in MDA-MB-231 or SKBR3 (Figure 3). We 
quantified the effect of the NO-specific scavenger Carboxy-PTIO for all three 
investigated cell lines. The concentration of the scavenger added was 1 mM for the 
first 4 h and 100 µM for the subsequent 20 h. The NO scavenger treatment by itself 
led to apoptosis enhancements of approximately 60% (MDA-MB-468), 50% 
(MDA-MB-231), 20% (SKBR3) (Figure 3). The apoptosis-enhancing effect of the 
NO scavenger implies that the NO concentrations in these cells lie in a range that 
is associated with a pro-survival (anti-apoptotic) role. After characterizing the 
separate effects of NP-EGF and NO scavenger, we next evaluated the synergistic 
effects that arise through combination of NP-EGF and Carboxy-PTIO. To that end, 
we co-incubated NP-EGF (100 pM) and NO scavenger (1 mM) with the cells for 4 
h and subsequently maintained the cells after removal of the NPs for another 20 h  
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Fig.  3-3  Apoptosis enhancement measured for basal, EGFR-overexpressing MDA-MB-
468, basal MDA-MB-231 with low EGFR expression, and luminal, EGFR-overexpressing 
SKBR3 for (from left to right): NO scavenger, NP-EGF (100 pM), NP-EGF + NO 
scavenger, 6 nM EGF, 6nM EGF + NO scavenger, 40 nM EGF, 40 nM EGF + NO 
scavenger. All experiments were performed as duplicates and repeated for six times. 
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3.3.3 in the presence of NO scavenger at a concentration of 100 µM. Intriguingly, 
addition of NP-EGF in the presence of NO scavenger dramatically increased 
apoptosis in MDA-MB-468 cells. We measured an average apoptosis enhancement 
of 300±73%. This strong increase was unique for the EGFR-overexpressing BLBC 
cell line MDA-MB-468. Neither the SKBR3 nor MDA-MB-231 cells showed a 
similar behavior; both had constant or even slightly declining apoptosis 
enhancements when treated with NO scavenger. Control experiments obtained with 
6 nM and 40 nM solutions of free EGF under otherwise identical conditions showed 
no detectable apoptosis enhancement for SKBR3 or MDA-MB-231 and only low 
enhancement for MDA-MB-468, confirming that the apoptosis enhancing effect in 
the presence of NO scavenger was unique to nanoconjugated EGF. 
 
Fig.  3-4 Characterization of EGFR and JNK phosphorylation through Western Blots. a) 
From top to bottom: phosphorylation of EGFR after 4h; phosphorylation of EGFR after 
24 h; phosphorylation of JNK after 4 h; phosphorylation of JNK after 24 h. NP-EGF 
concentration is 100pM. NO scavenger concentration is 1mM for the first 4 h and 100 µM 
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for the next 20 h incubation. AG1478 and JNK inhibitor concentrations are 500nM and 25 
µM, respectively for the entire 24 h of incubation. For pJNK the relative increase () or 
decrease () in intensity in % relative to the no treatment control are added for each band. 
b) Apoptosis enhancement of NP-EGF + NO scavenger and NP-EGF + NO scavenger + 
JNK inhibitor. 
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3.3.4 Effect of NO on MAPK Activation in EGFR-overexpressing MDA-MB-468.  
      Mitogen-activated protein kinases (MAPK) control important regulatory functions in 
cell growth, development and apoptosis and orchestrate cellular responses to external 
stress. It is known that MAPKs contribute to the control of cellular NO levels and that NO 
can activate several MAPK pathways.55-59 It is, thus, conceivable that MAPKs also play a 
role in facilitating the synergistic enhancement of apoptosis in the presence of both NP-
EGF and Carboxy-PTIO. To test this hypothesis, we analyzed the impact of NP-EGF +/-
Carboxy-PTIO on the activation (measured as phosphorylation) of the three main MAPK 
sub-families: extracellular signal-regulated protein kinase (ERK), p38, and c-Jun-terminal 
kinases (JNK). We did not detect any NP-EGF-induced changes in either ERK or p38 
activation levels (Figure S2), but for JNK, NP-EGF addition resulted in a measurable 
increase in phosphorylation. This is demonstrated in Figure 4a with Western Blots of 
phosphorylated EGFR and JNK under the specified conditions for two time points: 4 h and 
24 h. Free EGF with concentrations of 6 nM and 40 nM were added as controls. The 
Western Blots show that NP-EGF (effective EGF concentration of 6 nM) and 40 nM free 
EGF induce a strong increase in EGFR phosphorylation after 4 h. After 24 h the EGFR 
phosphorylation remains strong for NP-EGF and 40 nM free EGF only in the presence of 
NO scavenger. Thus, one effect of the NO scavenger is to induce increased levels of 
phosphorylated EGFR for prolonged times. 
Both NP-EGF and 40 nM free EGF also induce a measurable increase in phosphorylation 
of JNK at the 4 h time point in the presence or absence of NO scavenger. After 24 h the  
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Fig.  3-5 Western Blot analysis of S-nitrosylation of the lysate of NP-EGF treated cells (4 
h) for the conditions specified. 
JNK phosphorylation has overall decreased, but the phosphorylation for NP-EGF in the 
presence of NO scavenger remains higher than for all other experimental conditions. The 
phosphorylation in this case is 49% higher than for the no treatment control and 32% higher 
than for 40 nM free EGF with NO scavenger. We also evaluated the impact of NP-EGF 
and NO scavenger on the total JNK concentration, which is included in Figure S3. We did 
not detect any significant difference in total JNK concentration relative to the cell control 
for the investigated conditions.  
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Considering the pro-apoptotic function of JNK,60,61 the observation of increased levels of 
JNK activation over prolonged time as response to NP-EGF in the presence of NO 
scavenger provides a natural explanation for the observed apoptosis under these conditions. 
To further validate the model of a JNK-mediated apoptosis that is attenuated by NO, we 
measured the apoptosis for NP-EGF + NO scavenger in the absence and presence of JNK 
inhibitor (Figure 4b). Indeed, addition of JNK inhibitor effectively suppressed the 
observed apoptosis levels in response to NP-EGF.  
 
 
Fig.  3-6 Regulation model of NP-EGF-induced apoptosis. NP-EGF binding to EGFR 
triggers increased intracellular levels of NO and ROS. In the absence of NO scavenger 
NO nitrosylates JNK and blocks ROS-mediated activation. In the presence of NO 
scavenger, JNK can be phosphorylated and induces apoptosis. 
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3.3.5 Nitrosylation of JNK and its Role in Regulating NP-EGF-Induced Apoptosis. 
Why does addition of NO inhibitor increase JNK phosphorylation and, thus, 
enhance apoptotic signaling in response to NP-EGF?  It is well known that NO can 
nitrosylate thiols and that this oxidation can have regulatory functions. In fact, nitric 
oxide was shown in a different context to negatively regulate JNK (46 kDa) activity 
through S-nitrosylation.62 To validate the regulatory role of JNK nitrosylation in 
NP-EGF-induced apoptosis, we characterized protein nitrosylation through 
Western Blotting. Figure 5 shows the nitrosylation for the following conditions 
(left to right): cell control, carboxy-PTIO, NP-EGF, NP-EGF + carboxy-PTIO, 
AG1478, NP-EGF + Ag1478, 40 nM EGF+carboxy-PTIO. Both NP-EGF as well 
as 40 nM free EGF increase the overall nitrosylation but the effect is approximately 
50% stronger for NP-EGF. Importantly, addition of NO scavenger effectively 
blocked nitrosylation in both cases. Given the strong NP-EGF-induced 
nitrosylation and the effect of NO inhibitor, we suggest the regulation model shown 
in Figure 6 to account for the synergistic interplay between NP-EGF and NO 
inhibitor in enhancing apoptosis in MDA-MB-468. NP-EGF binding to EGFR in 
the plasma membrane of MDA-MB-468 results in increased intracellular levels of 
ROS and NO. The induced increased NO levels promote nitrosylation of JNK. 
Although high intracellular ROS levels in principle trigger apoptosis via JNK,60,63 
this signaling pathway is blocked due to JNK nitrosylation. If, however, 
nitrosylation is mitigated through addition of NO inhibitor, JNK phosphorylation 
is accessible and apoptosis related signaling is activated. Intriguingly, according to 
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this model one NP-EGF-induced reactive species (NO) down-regulates the 
apoptotic effect of the other reactive species (ROS), resulting in an effective 
attenuation of apoptosis signal in the cancer cell.  
 
3.4 Conclusion 
We have shown that EGF-presenting, lipid-wrapped PLGA NPs (NP-EGF) induce EGFR-
dependent apoptosis in the EGFR-overexpressing BLBC cell line MDA-MB-468. Under 
identical experimental conditions, NP-EGF did not induce apoptosis in BLBC cells with 
lower EGFR expression levels (MDA-MB-231) or Her2+ SKBR3 cells. For MDA-MB-
468, EGFR activation through NP-EGF triggered a strong increase in intracellular ROS 
and NO levels. The increase in NO was associated with a nitrosylation of JNK, which 
effectively blocked JNK activation. In the presence of NO inhibitor, this JNK inhibition 
was removed and JNK-mediated apoptosis occurred. BLBC is an aggressive cancer with 
poor prognosis and limited options for therapy,33,34 as BLBC cells have characteristically 
low expression levels of steroid hormone receptors and human epidermal growth factor 2 
(Her2), a subset of BLBCs overexpress, however, EGFR which makes them potential 
targets for NP-EGF.35 The synergistic interplay of NP-EGF with biodegradable polymer 
core and NO inhibitor to induce apoptosis selectively in EGFR overexpressing cells, 
demonstrated in this study, paves a new path towards inactivating at least a subset of 
BLBCs with targeted therapy. 
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